Akoya Biosciences, Inc. (AKYA)
Largest Insider Buys in Sector
AKYA Stock Price History Chart
AKYA Stock Performance
About Akoya Biosciences, Inc.
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue …
Insider Activity of Akoya Biosciences, Inc.
Over the last 12 months, insiders at Akoya Biosciences, Inc. have bought $0 and sold $203,317 worth of Akoya Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Akoya Biosciences, Inc. have bought $6.53M and sold $906,500 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $92,014 was made by Pla Frederic (Chief Operating Officer) on 2023‑09‑07.
List of Insider Buy and Sell Transactions, Akoya Biosciences, Inc.
| 2024-06-11 | Sale | President and CEO | 7,500 0.0145% | $2.08 | $15,630 | +17.81% | ||
| 2024-06-06 | Sale | President and CEO | 7,500 0.0146% | $2.01 | $15,064 | +23.21% | ||
| 2024-03-20 | Sale | President and CEO | 7,500 0.015% | $4.97 | $37,243 | -44.05% | ||
| 2024-03-13 | Sale | President and CEO | 7,500 0.0155% | $4.94 | $37,043 | -42.04% | ||
| 2023-12-19 | Sale | President and CEO | 7,500 0.0146% | $4.48 | $33,566 | -25.11% | ||
| 2023-12-12 | Sale | President and CEO | 7,500 0.0152% | $4.25 | $31,871 | -10.56% | ||
| 2023-11-20 | Sale | President and CEO | 7,500 0.0155% | $4.39 | $32,901 | -10.25% | ||
| 2023-09-07 | Chief Operating Officer | 20,000 0.0412% | $4.60 | $92,014 | -6.17% | |||
| 2023-09-07 | Chief Operating Officer | 13,000 0.0268% | $4.60 | $59,814 | -6.17% | |||
| 2023-06-12 | director | 2.02M 4.8443% | $5.00 | $10.1M | -13.79% | |||
| 2023-06-12 | director | 203,388 0.4878% | $5.00 | $1.02M | -13.79% | |||
| 2023-06-12 | director | 120,000 0.2878% | $5.00 | $600,000 | -13.79% | |||
| 2023-06-12 | director | 20,000 0.048% | $5.00 | $100,000 | -13.79% | |||
| 2023-06-12 | director | 20,000 0.048% | $5.00 | $100,000 | -13.79% | |||
| 2023-06-12 | CFO | 20,000 0.048% | $5.00 | $100,000 | -13.79% | |||
| 2023-06-06 | Sale | President/CEO | 5,000 0.0131% | $5.71 | $28,537 | -16.67% | ||
| 2023-03-14 | Sale | President/CEO | 5,000 0.0135% | $9.17 | $45,852 | -39.18% | ||
| 2022-12-14 | Sale | Chief Financial Officer | 14,574 0.0386% | $12.46 | $181,519 | -45.72% | ||
| 2022-12-13 | Sale | director | 71,050 0.1938% | $13.03 | $925,782 | -46.46% | ||
| 2022-12-13 | Sale | director | 100 0.0003% | $13.25 | $1,325 | -46.46% |
Insider Historical Profitability
| Raffin Thomas A. | director | 15937535 32.1974% | $2.41 | 1 | 0 | <0.0001% |
| Winkler Matthew | director | 984513 1.9889% | $2.41 | 1 | 0 | <0.0001% |
| SHEPLER ROBERT G | director | 369592 0.7467% | $2.41 | 2 | 0 | <0.0001% |
| Mendel Scott | director | 28500 0.0576% | $2.41 | 2 | 0 | <0.0001% |
| Ramachandran Niro Ph.D | Chief Business Officer | 25073 0.0507% | $2.41 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Blue Water Life Science Advisors Llc | $22.03M | 9.51 | 4.7M | 0% | +$0 | 20.72 | |
| Polar Capital | $7.41M | 3.2 | 1.58M | 0% | +$0 | 0.04 | |
| The Vanguard Group | $6.82M | 2.95 | 1.45M | +3.28% | +$216,354.40 | <0.0001 | |
| BlackRock | $6.32M | 2.73 | 1.35M | -1.8% | -$115,810.17 | <0.0001 | |
| Parkman Healthcare Partners Llc | $4.3M | 1.86 | 917,442 | +35.96% | +$1.14M | 0.54 |